14,390

Views

CrossRef citations to date

Altmetric

Original research

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

Christian KleinRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, SwitzerlandCorrespondence[email protected]

Inja WaldhauerRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland

Valeria G. NicoliniRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland

Anne Freimoser-GrundschoberRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland

Tapan NayakRoche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland

Danielle J. VugtsRoche Pharma Research & Early Development, Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands

Claire DunnRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland

Marije BolijnRoche Pharma Research & Early Development, Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands

Jörg BenzRoche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland

Martine StihleRoche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland

Sabine LangRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland

Michaele RoemmeleRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland

Thomas HoferRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland

Erwin van PuijenbroekRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland

David WittigRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland

http://orcid.org/0000-0002-3296-6809

Samuel MoserRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland

Oliver AstRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland

Peter BrünkerRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland

Ingo H. GorrRoche Pharma Research & Early Development, Roche Innovation Center Munich, Penzberg, Germany

Sebastian NeumannRoche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland

Maria Cristina de Vera MudryRoche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland

http://orcid.org/0000-0003-1016-7480

Heather HintonRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland

Flavio CrameriRoche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland

Jose SaroRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland

http://orcid.org/0000-0003-0778-3864

Stefan EversRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland

http://orcid.org/0000-0001-9587-5325

Christian GerdesRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland

Marina BacacRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland

Guus van DongenRoche Pharma Research & Early Development, Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands

Ekkehard MoessnerRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland

Pablo UmañaRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, SwitzerlandCorrespondence[email protected]

show all

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

Supplemental_materials.zip

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

Supplemental_materials.zip

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date